NY State Senate Bill S5216

Archive: Last Bill Status - Signed by Governor

Introduced
In Committee
On Floor Calendar
- Passed Senate
- Passed Assembly
Delivered to Governor
Signed by Governor

Your Voice

Please enter your contact information

First Name *

Last Name *

Email Address *

A valid email address is required.

Home address search or enter your address manually *

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Leave this field blank

Actions

view actions (17)

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Nov 28, 2016	signed chap.479
Nov 16, 2016	delivered to governor
Jun 15, 2016	returned to senate passed assembly ordered to third reading rules cal.330 substituted for a3072a
Jun 08, 2016	referred to ways and means delivered to assembly passed senate
Jun 07, 2016	ordered to third reading cal.1490 committee discharged and committed to rules
May 16, 2016	print number 5216a
May 16, 2016	amend and recommit to finance
May 04, 2016	reported and committed to finance
Jan 06, 2016	referred to health
May 28, 2015	reported and committed to finance
May 07, 2015	referred to health

Votes

view votes

Jun 8, 2016 - floor Vote

S5216A

floor

Aye

Nay

Absent

Excused

Abstained

Jun 7, 2016 - Rules committee Vote

S5216A

committee

Aye

Nay

Aye with Reservations

Absent

Excused

Abstained

May 4, 2016 - Health committee Vote

S5216

committee

Aye

Nay

Aye with Reservations

Absent

Excused

Abstained

May 28, 2015 - Health committee Vote

S5216

committee

Aye

Nay

Aye with Reservations

Absent

Excused

Abstained

Bill Amendments

Original

A (Active)

Original

A (Active)

Co-Sponsors

view additional co-sponsors

S5216 - Details

See Assembly Version of this Bill:: A3072
Law Section:: Public Health Law
Laws Affected:: Amd §207, Pub Health L
Versions Introduced in Other Legislative Sessions:: 2009-2010: S3679, A8884
2011-2012: S5114, A459
2013-2014: S5178, A544, A8461

S5216 - Summary

Creates an education and outreach program for the autoimmune disease known as lupus; provides for an advisory council consisting of representatives of people with lupus and their families and health care providers who specialize in treating lupus.

S5216 - Sponsor Memo

BILL NUMBER:S5216

TITLE OF BILL:

An act to amend the public health law, in relation to the lupus
education and outreach program

PURPOSE:

To create a statewide program within the Department of Health to
promote awareness to the public and health care professionals
concerning the causes and consequences of Lupus.

SUMMARY OF SPECIFIC PROVISIONS:

The Commissioner of Health shall establish, promote and maintain,
within the department, a Lupus education and awareness program with an
emphasis on minority populations and at risk communities to raise
public awareness, educate consumers, and educate and train health
professionals, human services providers and other audiences. This bill
also allows the Department to accept gifts, grants, and donations from
the federal government, foundations or other organizations and
entities for fulfilling the obligations of the program.

JUSTIFICATION:

Lupus is a chronic inflammatory disease that can affect various parts
of the body, especially the skin, joints, blood and kidneys. Lupus is
often called a "Women's Disease" despite the fact that many men are
affected. Lupus affects more than 1.5 million people in the United
States. Lupus can occur at any age, and in either sex, although it
occurs 10-15 times more frequently among adult females than among
adult males after puberty. About 9 out of 10 people who have Lupus are
women. Lupus is three times more common in black women than in white
women. It is also more common in women of Hispanic/Latina, Asian, and
American Indian descent. Black and Hispanic/Latina women tend to
develop symptoms at an earlier age than other women.

PRIOR LEGISLATIVE HISTORY:

2009-10: A.5854-Referred to Health, Reported to Ways and Means/
S.3679-Referred to Health,
2011-12:  A.459-Referred to Health, Reported Ways and Means, Passed
Assembly/ S. 5114-Referred to Health, Reported-Finance A.8461 of 2014
referred to Health/ S.5178 referred to health. Reported and committed
to Finance.

FISCAL IMPLICATIONS:

None to the state/local

EFFECTIVE DATE:

This Act shall take effect immediately.

S5216 - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  5216

                       2015-2016 Regular Sessions

                            I N  S E N A T E

                               May 7, 2015
                               ___________

Introduced  by  Sen.  SAVINO -- read twice and ordered printed, and when
  printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to the  lupus  educa-
  tion and outreach program

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1.  Legislative  intent.  The  legislature  hereby  finds  the
following:
  (a)  Lupus is a serious, complex, debilitating autoimmune disease that
can cause inflammation and tissue damage to virtually any  organ  system
in  the body, including the skin, joints, other connective tissue, blood
and blood vessels, heart, lungs, kidney, and brain.
  (b) Lupus research estimates that approximately one and a half to  two
million Americans live with some form of lupus; lupus affects women nine
times more often than men and eighty percent of newly diagnosed cases of
lupus develop among women of childbearing age.
  (c)  Lupus  disproportionately  affects women of color -- it is two to
three times more common among African-Americans, Hispanics,  Asians  and
Native Americans and is generally more prevalent in minority populations
-- a health disparity that remains unexplained. According to the Centers
for  Disease  Control  and  Prevention  the  rate of lupus mortality has
increased since the late 1970s and is higher among older  African-Ameri-
can women.
  (d) No new drugs have been approved by the U.S. Food and Drug Adminis-
tration  specifically  for lupus in nearly forty years and while current
treatments for the disease can be effective, they can lead  to  damaging
side effects.
  (e)  The  pain and fatigue associated with lupus can threaten people's
ability to live independently, make it difficult to maintain  employment
and  lead normal lives, and one in five people with lupus is disabled by
the disease, and consequently receives support from government programs,

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD01779-01-5

S. 5216                             2

including Medicare, Medicaid, social  security  disability,  and  social
security supplemental income.
  (f)  The  estimated  average  annual  cost of medical treatment for an
individual with lupus can range between ten thousand dollars and  thirty
thousand  dollars;  for  people who have the most serious form of lupus,
medical costs can greatly exceed  this  amount,  causing  a  significant
economic, emotional and social burden to the entire family and society.
  (g)  More than half of the people with lupus suffer four or more years
and visit three or more  physicians  before  obtaining  a  diagnosis  of
lupus;  early  diagnosis  of and commencement of treatment for lupus can
prevent or reduce serious organ damage, disability, and death.
  (h) Despite the magnitude of lupus and its impact on  individuals  and
families,  health professional and public understanding of lupus remains
low; only one of five Americans can provide even basic information about
lupus, and awareness of lupus is lowest among adults  ages  eighteen  to
thirty-four -- the age group most likely to develop symptoms of lupus.
  (i)  Lupus  is  a  significant  national  health issue that deserves a
comprehensive and coordinated response by state and federal  governments
with involvement of the health care provider, patient, and public health
communities.
  S  2. Subdivision 1 of section 207 of the public health law is amended
by adding a new paragraph (k) to read as follows:
  (K) LUPUS, A DEBILITATING AUTOIMMUNE DISEASE THAT CAN CAUSE  INFLAMMA-
TION  AND  TISSUE  DAMAGE  TO  VIRTUALLY  ANY  ORGAN SYSTEM IN THE BODY,
INCLUDING THE SKIN, JOINTS, OTHER CONNECTIVE  TISSUE,  BLOOD  AND  BLOOD
VESSELS, HEART, LUNG, KIDNEY AND BRAIN, AND WHICH AFFECTS WOMEN, PARTIC-
ULARLY  WOMEN  OF COLOR, IN A DISPROPORTIONATE MANNER; PROVIDED THAT THE
PROGRAM SHALL INCLUDE AN ADVISORY COUNCIL UNDER THIS SECTION THAT  SHALL
INCLUDE  REPRESENTATIVES  OF  PEOPLE  WITH  LUPUS AND THEIR FAMILIES AND
HEALTH CARE PROVIDERS WHO SPECIALIZE IN TREATING LUPUS, AMONG OTHERS.
  S 3. Subdivision 7 of section 207 of the public health law, as amended
by section 16 of part A of chapter 109 of the laws of 2010,  is  amended
to read as follows:
  7.  In  addition  to  state funds appropriated for programs under this
section, the commissioner may  accept  grants  from  public  or  private
sources  for  these  programs.  The  commissioner, in administering this
section, shall seek to coordinate the department's programs  with  other
public  and  private  programs,  and  may undertake joint or cooperative
programs with other public or private entities, INCLUDING MAKING  GRANTS
(WITHIN  AMOUNTS  APPROPRIATED  THEREFOR  AND CONSISTENT WITH APPLICABLE
LAW) TO PUBLIC OR NOT-FOR-PROFIT ENTITIES.
  S 4. This act shall take effect immediately.

Co-Sponsors

view additional co-sponsors

S5216A (ACTIVE) - Details

See Assembly Version of this Bill:: A3072
Law Section:: Public Health Law
Laws Affected:: Amd §207, Pub Health L
Versions Introduced in Other Legislative Sessions:: 2009-2010: S3679, A8884
2011-2012: S5114, A459
2013-2014: S5178, A544, A8461

S5216A (ACTIVE) - Summary

S5216A (ACTIVE) - Sponsor Memo

 BILL NUMBER:  S5216A

 TITLE OF BILL :

An act to amend the public health law, in relation to the lupus
education and outreach program

 PURPOSE :

To create a statewide program within the Department of Health to
promote awareness to the public and health care professionals
concerning the causes and consequences of Lupus.

 SUMMARY OF SPECIFIC PROVISIONS :

The Public Health Law § 207 provides for the Health Care and Wellness
Education and Outreach Program within the department the health to
conduct education and outreach programs for consumers, patients,
educators, including but not limited to elementary and secondary
school educators, and health care providers relating to any health
care matters the commissioner deems appropriate.

Subdivision 1 of § 207 of the Public Health Law is amended by adding a
new paragraph (m) to read as follows:

 (M) LUPUS, A DEBILITATING AUTOIMMUNE DISEASE THAT CAN CAUSE

INFLAMMATION AND TISSUE DAMAGE TO VIRTUALLY ANY ORGAN SYSTEM IN THE
BODY, INCLUDING THE SKIN, JOINTS, OTHER CONNECTIVE TISSUE, BLOOD AND
BLOOD VESSELS, HEART, LUNG, KIDNEY AND BRAIN, AND WHICH AFFECTS WOMEN,
PARTICULARLY WOMEN OF COLOR, IN A DISPROPORTIONATE MANNER; PROVIDED
THAT THE PROGRAM SHALL INCLUDE AN ADVISORY COUNCIL UNDER THIS SECTION
THAT SHALL INCLUDE REPRESENTATIVES OF PEOPLE WITH LUPUS AND THEIR
FAMILIES AND HEALTH CARE PROVIDERS WHO SPECIALIZE IN TREATING LUPUS,
AMONG OTHERS.

This bill will authorize the Commissioner of Health to establish The
Lupus Education and Outreach Program with the goal to raise public
awareness and educate consumers. The program will support efforts to
further assist health care professionals, public health specialists,
human services providers, and those in related fields to recognize the
illness as Lupus. It will also put an emphasis on women and
minorities, who are at the highest risk for developing this illness.

In addition to state funds appropriated for programs under this
section, the department may undertake joint or cooperative programs
with other public or private entities and the federal government. The
department will also be authorized to accept gifts, grants and
donations from foundations and other public or private entities.

 JUSTIFICATION :

Lupus is a chronic inflammatory and debilitating autoimmune disease
that affects various parts of the body, especially the skin, joints,
blood and kidneys. It is unpredictable, highly individualized, and
potentially fatal. Lupus is not easily diagnosed, and there is no
known cause or cure.

*Lupus affects more than 1.5 million people in the United States

*Although it can occur at any age, 80% of new cases develop between
the ages of 15 and 44 - during the prime of life

*It occurs 10-15 times more frequently among adult females than among
adult males after puberty

*Approximately 9 out of 10 people who have Lupus are women
*It is 3 times more common in African American women than in Caucasian
women, and also more common in women of Hispanic/Latina, Asian, and
American Indian descent

*African American and Hispanic/Latina women tend to develop symptoms
at an earlier age than other women

*Lupus is a leading cause of kidney disease, stroke and premature
cardiovascular disease in young women

Lupus suffers from the lack of awareness more than any other major
disease. It can mirror other illnesses, therefore the symptoms may be
treated separately, most of the time with little or no results. It may
take years of visiting numerous physicians of various specialties to
identify the illness as Lupus. Consequently, patients do not receive
the already limited amount of treatment available while their health
is further deteriorating.

A statewide education and outreach program to stress the urgent need
for increased public and professional awareness is paramount to early
diagnosis and treatment, thereby providing much relief of the
physical, emotional and economic impact for those suffering this
dreadful disease.

 LEGISLATIVE HISTORY :

 SENATE :

5/4/16 - Reported from Health, committed to Finance.
2015, 2014, 2012, 2011 - Reported from Health, committed to Finance.

 ASSEMBLY :

A3072 Peoples-Stokes
2016 - Reported from Health, reported to Assembly Ways and Means
2015 - Reported from Health, reported to Assembly Ways and Means
2014 - Referred to Health
2012 and 2011 - PASSED ASSEMBLY (Gibson A459).

 FISCAL IMPLICATIONS :

Minimal, and to be determined based upon the authorized collaboration
with outside funding resources.

 EFFECTIVE DATE :
Immediately.

S5216A (ACTIVE) - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 5216--A

                       2015-2016 Regular Sessions

                            I N  S E N A T E

                               May 7, 2015
                               ___________

Introduced  by  Sens.  SAVINO, ADDABBO, AVELLA, COMRIE, CROCI, GALLIVAN,
  GOLDEN, GRIFFO, HANNON, KENNEDY, KLEIN,  LATIMER,  PANEPINTO,  PARKER,
  PERALTA, PERKINS, RANZENHOFER, RITCHIE, STAVISKY, VALESKY, VENDITTO --
  read  twice  and  ordered printed, and when printed to be committed to
  the Committee on Health -- recommitted to the Committee on  Health  in
  accordance  with Senate Rule 6, sec. 8 -- reported favorably from said
  committee and committed to  the  Committee  on  Finance  --  committee
  discharged, bill amended, ordered reprinted as amended and recommitted
  to said committee

AN  ACT  to amend the public health law, in relation to the lupus educa-
  tion and outreach program

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.  Legislative  intent.  The  legislature  hereby  finds the
following:
  (a) Lupus is a serious, complex, debilitating autoimmune disease  that
can  cause  inflammation and tissue damage to virtually any organ system
in the body, including the skin, joints, other connective tissue,  blood
and blood vessels, heart, lungs, kidney, and brain.
  (b)  Lupus research estimates that approximately one and a half to two
million Americans live with some form of lupus; lupus affects women nine
times more often than men and eighty percent of newly diagnosed cases of
lupus develop among women of childbearing age.
  (c) Lupus disproportionately affects women of color -- it  is  two  to
three  times  more common among African-Americans, Hispanics, Asians and
Native Americans and is generally more prevalent in minority populations
-- a health disparity that remains unexplained. According to the Centers
for Disease Control and Prevention  the  rate  of  lupus  mortality  has
increased  since the late 1970s and is higher among older African-Ameri-
can women.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD01779-02-6

S. 5216--A                          2

  (d) No new drugs have been approved by the U.S. Food and Drug Adminis-
tration specifically for lupus in nearly forty years and  while  current
treatments  for  the disease can be effective, they can lead to damaging
side effects.
  (e)  The  pain and fatigue associated with lupus can threaten people's
ability to live independently, make it difficult to maintain  employment
and  lead normal lives, and one in five people with lupus is disabled by
the disease, and consequently receives support from government programs,
including Medicare, Medicaid, social  security  disability,  and  social
security supplemental income.
  (f)  The  estimated  average  annual  cost of medical treatment for an
individual with lupus can range between ten thousand dollars and  thirty
thousand  dollars;  for  people who have the most serious form of lupus,
medical costs can greatly exceed  this  amount,  causing  a  significant
economic, emotional and social burden to the entire family and society.
  (g)  More than half of the people with lupus suffer four or more years
and visit three or more  physicians  before  obtaining  a  diagnosis  of
lupus;  early  diagnosis  of and commencement of treatment for lupus can
prevent or reduce serious organ damage, disability, and death.
  (h) Despite the magnitude of lupus and its impact on  individuals  and
families,  health professional and public understanding of lupus remains
low; only one of five Americans can provide even basic information about
lupus, and awareness of lupus is lowest among adults  ages  eighteen  to
thirty-four -- the age group most likely to develop symptoms of lupus.
  (i)  Lupus  is  a  significant  national  health issue that deserves a
comprehensive and coordinated response by state and federal  governments
with involvement of the health care provider, patient, and public health
communities.
  S  2. Subdivision 1 of section 207 of the public health law is amended
by adding a new paragraph (m) to read as follows:
  (M) LUPUS, A DEBILITATING AUTOIMMUNE DISEASE THAT CAN CAUSE  INFLAMMA-
TION  AND  TISSUE  DAMAGE  TO  VIRTUALLY  ANY  ORGAN SYSTEM IN THE BODY,
INCLUDING THE SKIN, JOINTS, OTHER CONNECTIVE  TISSUE,  BLOOD  AND  BLOOD
VESSELS, HEART, LUNG, KIDNEY AND BRAIN, AND WHICH AFFECTS WOMEN, PARTIC-
ULARLY  WOMEN  OF COLOR, IN A DISPROPORTIONATE MANNER; PROVIDED THAT THE
PROGRAM SHALL INCLUDE AN ADVISORY COUNCIL UNDER THIS SECTION THAT  SHALL
INCLUDE  REPRESENTATIVES  OF  PEOPLE  WITH  LUPUS AND THEIR FAMILIES AND
HEALTH CARE PROVIDERS WHO SPECIALIZE IN TREATING LUPUS, AMONG OTHERS.
  S 3. Subdivision 7 of section 207 of the public health law, as amended
by section 16 of part A of chapter 109 of the laws of 2010,  is  amended
to read as follows:
  7.  In  addition  to  state funds appropriated for programs under this
section, the commissioner may  accept  grants  from  public  or  private
sources  for  these  programs.  The  commissioner, in administering this
section, shall seek to coordinate the department's programs  with  other
public  and  private  programs,  and  may undertake joint or cooperative
programs with other public or private entities, INCLUDING MAKING  GRANTS
(WITHIN  AMOUNTS  APPROPRIATED  THEREFOR  AND CONSISTENT WITH APPLICABLE
LAW) TO PUBLIC OR NOT-FOR-PROFIT ENTITIES.
  S 4. This act shall take effect immediately.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

The New York State Senate

senate Bill S5216

Sponsored By

Archive: Last Bill Status - Signed by Governor

Your Voice

Actions

Votes

Jun 8, 2016 - floor Vote

Floor Vote: Jun 8, 2016

Jun 7, 2016 - Rules committee Vote

Committee Vote: Jun 7, 2016

May 4, 2016 - Health committee Vote

Health Committee Vote: May 4, 2016

May 28, 2015 - Health committee Vote

Health Committee Vote: May 28, 2015

Bill Amendments

Co-Sponsors

S5216 - Details

S5216 - Summary

S5216 - Sponsor Memo

S5216 - Bill Text download pdf

Co-Sponsors

S5216A (ACTIVE) - Details

S5216A (ACTIVE) - Summary

S5216A (ACTIVE) - Sponsor Memo

S5216A (ACTIVE) - Bill Text download pdf

Comments

senate Bill S5216

Share this bill

Sponsored By

Archive: Last Bill Status - Signed by Governor

Your Voice

Actions

Votes

Jun 8, 2016 - floor Vote

Floor Vote: Jun 8, 2016

Jun 7, 2016 - Rules committee Vote

Committee Vote: Jun 7, 2016

May 4, 2016 - Health committee Vote

Health Committee Vote: May 4, 2016

May 28, 2015 - Health committee Vote

Health Committee Vote: May 28, 2015

Bill Amendments

Co-Sponsors

S5216 - Details

S5216 - Summary

S5216 - Sponsor Memo

S5216 - Bill Text download pdf

Co-Sponsors

S5216A (ACTIVE) - Details

S5216A (ACTIVE) - Summary

S5216A (ACTIVE) - Sponsor Memo

S5216A (ACTIVE) - Bill Text download pdf

Comments